Critical Comparison: Ceapro (OTCMKTS:CRPOF) vs. Histogen (NASDAQ:HSTO)

Valuation and Earnings

This table compares Ceapro and Histogen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ceapro	$7.14 million	1.86	-$3.49 million	($0.06)	-2.83
Histogen	$19,000.00	0.28	-$10.62 million	($2.81)	0.00

Ceapro has higher revenue and earnings than Histogen. Ceapro is trading at a lower price-to-earnings ratio than Histogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ceapro has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Histogen has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Profitability

This table compares Ceapro and Histogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ceapro	-69.60%	-20.30%	-18.07%
Histogen	N/A	N/A	N/A

Summary

Ceapro beats Histogen on 5 of the 9 factors compared between the two stocks.

About Ceapro

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

About Histogen

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.